Trial Profile
A Phase 4, Open-label Field Study (200137) to Evaluate the Clinical Benefit, Safety and Pharmacokinetics in Subjects Treated With Raxibacumab (GSK3068483) Following Exposure to Bacillus Anthracis
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Raxibacumab (Primary)
- Indications Anthrax
- Focus Therapeutic Use
- Sponsors GSK
- 01 Oct 2020 Planned initiation date changed from 1 Sep 2019 to 1 Sep 2021.
- 25 Sep 2018 Planned End Date changed from 1 Apr 2021 to 1 Jul 2025.
- 25 Sep 2018 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2025.